Metastatic Breast Cancer

Among patients with metastatic breast cancer, oral paclitaxel and encequidar demonstrated superior tumor response rate compared with IV paclitaxel, according to research presented at ASCO 2021.

HER2–low expression was linked to inferior progression-free survival among breast cancer patients with estrogen receptor-positive, HER2-negative metastatic disease treated with CDK4/6 inhibitors, according to research presented at ASCO 2021.

Pembrolizumab demonstrated antitumor activity among women with heavily pretreated metastatic breast cancer characterized by high tumor mutational burden, according to phase 2 results from the TAPUR basket study.

In this video, Kelly K. Hunt, MD, FACS, FSSO, professor and chair of the department of breast surgical oncology at The University of Texas MD Anderson Cancer Center, spoke with Healio on her predictions of hot topics in metastatic breast cancer at the 38th Annual Miami Breast Cancer Conference.

Most women with metastatic breast cancer require opioids for pain management within a month of diagnosis, according to observational study results published in Scientific Reports.

Nancy U. Lin, MD, spoke with Healio about the advances and challenges in the treatment of HER2-positive metastatic breast cancer.

The addition of tesetaxel to reduced-dose capecitabine improved PFS among women with HER2-negative, hormone receptor-positive metastatic breast cancer, according to study results presented at the virtual San Antonio Breast Cancer Symposium.

Women with metastatic triple-negative breast cancer benefited from sacituzumab govitecan irrespective of their Trop-2 expression level and BRCA1/BRCA2 mutation status, according to data from the phase 3 ASCENT study.

An updated analysis of the phase 2 DESTINY-Breast01 study showed fam-trastuzumab deruxtecan-nxki continued to benefit women with heavily pretreated HER2-positive metastatic breast cancer.

Circulating tumor cell assessments a month after treatment initiation predicted survival among patients with metastatic breast cancer, according to findings presented at the virtual San Antonio Breast Cancer Symposium.